title: Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors.
abstract: Neuroendocrine tumors (NETs) are rare epithelial neoplasms with neuroendocrine differentiation originating most commonly in the lungs and gastroenteropancreatic. Treatment includes surgery and other local therapies; treatment of inoperable disease centers around symptom management and control of tumor growth. Somatostatin analogues (SSAs) have been a mainstay of managing hormone-related symptoms. Emerging evidence suggests that they are effective therapies for tumor control also. Peptide receptor radionuclide therapy with radiolabeled SSAs is a new, promising treatment for inoperable or metastatic NETs. This article reviews the role of SSAs in the treatment of NETs.
authors.affiliation: Medicine/Oncology, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305-5826, USA.
authors.forename: Sujata
authors.initials: S
authors.lastname: Narayanan
authors.affiliation: Medicine/Oncology, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305-5826, USA. Electronic address: pkunz@stanford.edu.
authors.forename: Pamela L
authors.initials: PL
authors.lastname: Kunz
mesh_terms: D018572:Disease-Free Survival; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods* / Q000639:trends; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000378:metabolism; D016032:Randomized Controlled Trials as Topic; D017481:Receptors, Somatostatin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D017481:Receptors, Somatostatin; D013004:Somatostatin
keywords: Carcinoid syndrome; Neuroendocrine tumors; Peptide receptor radionuclide therapy; Somatostatin analogues; Somatostatin receptors